Constellation soars 110% after reporting new data from myelofibrosis trial
Constellation Pharmaceuticals announced earlier that abstracts with preliminary data from the Manifest clinical trial from 59 enrolled patients as of June 27, 2019, the data cutoff date, were published today in association with the Society of Hematology meeting. In Arm 3, which evaluates CPI-0610 for myelofibrosis in combination with ruxolitinib in a first-line setting in JAK-inhibitor-naive patients, all four evaluable patients experienced at least a 35% spleen volume reduction and at least a 50% reduction in total symptom score, which are the primary endpoints for these patients, the compamy said. In Arms 1 and 2, which are evaluating CPI-0610 in combination with ruxolitinib and as a monotherapy in a second-line setting in ruxolitinib-resistant or -intolerant patients, "additional preliminary data showed continuing signs of activity across a broad range of parameters, including spleen volume reduction, patient-reported symptom improvement, hemoglobin increases, conversion to transfusion independence in transfusion-dependent patients, and bone marrow fibrosis score improvement, consistent with preliminary data presented at ASCO and EHA in June," according to Constellation. The company noted that CPI-0610 was generally well-tolerated, both as a monotherapy or in combination with ruxolitinib. One ruxolitinib-resistant or -intolerant patient discontinued due to serious adverse event, which were reported as unlikely related to CPI-0610. No JAK-inhibitor-naive patients discontinued due to adverse events.